PPARα inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a

Journal of Clinical Investigation

Volumn 115, Issue 11, 2005, Pages 3228-3238

  Gizard, Florence ^a   Amant, Carole ^b   Barbier, Olivier ^a   Bellosta, Stefano ^c   Robillard, Romain ^a   Percevault, Frédéric ^a   Sevestre, Henry ^b   Krimpenfort, Paul ^d   Corsini, Alberto ^c   Rochette, Jacques ^b   Glineur, Corine ^a   Fruchart, Jean Charles ^a   Torpier, Gérard ^a   Staels, Bart ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^c UNIVERSITY OF MILAN   (Italy)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; DIMETHYL SULFOXIDE; FENOFIBRATE; GREEN FLUORESCENT PROTEIN; GW 7647; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; PROTEIN P16INK4A; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR SP1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL OCCLUSION; CAROTID ARTERY INJURY; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HELA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; VASCULAR SMOOTH MUSCLE;

ANIMALS; CAROTID ARTERY INJURIES; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DOWN-REGULATION; G1 PHASE; GROWTH INHIBITORS; HELA CELLS; HUMANS; HYPERPLASIA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; PPAR ALPHA; RETINOBLASTOMA PROTEIN; S PHASE; TRANSCRIPTION, GENETIC; TUNICA INTIMA; UP-REGULATION;

EID: 27644590901     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI22756     Document Type: Article

References (64)

1. Dzau, V.J., Braun-Dullaeus, R.C., and Sedding, D.G. 2002. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat. Med. 8:1249-1256.
2. Hao, H., Gabbiani, G., and Bochaton-Piallat, M.L. 2003. Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development. Arterioscler. Thromb. Vasc. Biol. 23:1510-1520.
3. Ross, R. 1999. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340:115-126.
4. Yoshida, T., and Owens, G.K. 2005. Molecular determinants of vascular smooth muscle cell diversity. Circ. Res. 96:280-291.
5. Walworth, N.C. 2000. Cell-cycle checkpoint kinases: checking in on the cell cycle. Curr. Opin. Cell Biol. 12:697-704.
6. Harbour, J.W., and Dean, D.C. 2000. Rb function in cell-cycle regulation and apoptosis. Nat. Cell Biol. 2:E65-E67.
7. Ekholm, S.V., and Reed, S.I. 2000. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr. Opin. Cell Biol. 12:676-684.
8. Serrano, M., Hannon, G.J., and Beach, D. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:704-707.
9. Tam, S.W., Shay, J.W., and Pagano, M. 1994. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. Cancer Res. 54:5816-5820.
10. Parry, D., Bates, S., Mann, D.J., and Peters, G. 1995. Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J. 14:503-511.
11. Hara, E., et al. 1996. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol. Cell. Biol. 16:859-867.
12. Michalik, L., Desvergne, B., and Wahli, W. 2004. Peroxisome-proliferator- activated receptors and cancers: complex stories. Nat. Rev. Cancer. 4:61-70.
13. Marx, N., Duez, H., Fruchart, J.C., and Staels, B. 2004. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res. 94:1168-1178.
14. Brown, W.V. 1987. Potential use of fenofibrate and other fibric acid derivatives in the clinic. Am. J. Med. 83:85-89.
15. Willson, T.M., Brown, P.J., Sternbach, D.D., and Henke, B.R. 2000. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43:527-550.
16. Robins, S.J., et al. 2001. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 285:1585-1591.
17. Steiner, G. 1996. The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group. Diabetologia. 39:1655-1661.
18. Frick, M.H., et al. 1997. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation. 96:2137-2143.
19. Ericsson, C.G., et al. 1996. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 347:849-853.
20. Staels, B., et al. 1998. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 98:2088-2093.
21. Zahradka, P., et al. 2003. Activation of peroxisome proliferator- activated receptors alpha and gamma1 inhibits human smooth muscle cell proliferation. Mol. Cell. Biochem. 246:105-110.
22. Staels, B., et al. 1998. Activation of human aortic smooth-muscle cells is inhibited by PPAR-alpha but not by PPARgamma activators. Nature. 393:790-793.
23. Marx, N., Schonbeck, U., Lazar, M.A., Libby, P., and Plutzky, J. 1998. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res. 83:1097-1103.
24. Nigro, J., Dilley, R.J., and Little, P.J. 2002. Differential effects of gemfibrozil on migration, proliferation and proteoglycan production in human vascular smooth muscle cells. Atherosclerosis. 162:119-129.
25. Brown, P.J., et al. 2001. Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis. Bioorg. Med. Chem. Lett. 11:1225-1227.
26. Myohanen, S., and Baylin, S.B. 2001. Sequence-specific DNA binding activity of RNA helicase A to the p16INK4a promoter. J. Biol. Chem. 276:1634-1642.
27. Sherr, C.J., and Roberts, J.M. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1501-1512.
28. Kitagawa, M., et al. 1996. The consensus motif for phosphorylation by cyclin Dl-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J. 15:7060-7069.
29. Krimpenfort, P., Quon, K.C., Mooi, W.J., Loonstra, A., and Berns, A. 2001. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature. 413:83-86.
30. Carmeliet, P., et al. 1997. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ. Res. 81:829-839.
31. Wang, X., and Paigen, B. 2002. Comparative genetics of atherosclerosis and restenosis: exploration with mouse models. Arterioscler. Thromb. Vasc. Biol. 22:884-886.
32. Kuhel, D.G., Zhu, B., Witte, D.P., and Hui, D.Y. 2002. Distinction in genetic determinants for injury-induced neointimal hyperplasia and diet-induced atherosclerosis in inbred mice. Arterioscler. Thromb. Vasc. Biol. 22:955-960.
33. Gonzalez, F.J., Peters, J.M., and Cattley, R.C. 1998. Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha. J. Natl. Cancer Inst. 90:1702-1709.
34. Kockx, M., et al. 1999. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. Blood. 93:2991-2998.
35. Saitoh, K., et al. 1995. Anti-atheromatous effects of fenofibrate, a hypolipidemic drug. I: Anti-atheromatous effects are independent of its hypolipidemic effect in cholesterol-fed rabbits [In Japanese]. Nippon Yakurigaku Zasshi. 106:41-50.
36. Saitoh, K., Mori, T., Kasai, H., Nagayama, T., and Ohbayashi, S. 1995. Anti-atheromatous effects of fenofibrate, a hypolipidemic drug. II: Anti-atheromatous effects are independent of its hypolipidemic effect in hereditary hyperlipidemic rabbits [In Japanese]. Nippon Yakurigaku Zasshi. 106:51-60.
37. Rubins, H.B., et al. 1999. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341:410-418.
38. Ross, J.S., Stagliano, N.E., Donovan, M.J., Breitbart, R.E., and Ginsburg, G.S. 2001. Atherosclerosis and cancer: common molecular pathways of disease development and progression. Ann. N. Y. Acad. Sci. 947:271-292; discussion 292-293.
39. Wakino, S., et al. 2000. Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1→S transition in vascular smooth muscle cells. J. Biol. Chem. 275:22435-22441.
40. Tanner, F.C., et al. 2000. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation. 101:2022-2025.
41. Boehm, M., et al. 2004. Bone marrow-derived immune cells regulate vascular disease through a p27(Kip1)-dependent mechanism. J. Clin. Invest. 114:419-426. doi:10.1172/JCI200420176.
42. Belinsky, S.A., et al. 1998. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad. Sci. U. S. A. 95:11891-11896.
43. Nuovo, G.J., Plaia, T.W., Belinsky, S.A., Baylin, S.B., and Herman, J.G. 1999. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc. Natl. Acad. Sci. U. S. A. 96:12754-12759.
44. Wong, D.J., Foster, S.A., Galloway, D.A., and Reid, BJ. 1999. Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest. Mol. Cell Biol. 19:5642-5651.
45. Sharpless, N.B., and DePinho, R.A. 1999. The INK4A/ARF locus and its two gene products. Curr. Opin. Genet. Dev. 9:22-30.
46. Kersten, S., et al. 1999. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J. Clin. Invest. 103:1489-1498.
47. Guerre-Millo, M., et al. 2001. PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes. 50:2809-2814.
48. Devchand, P.R., et al. 1996. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature. 384:39-43.
49. Gervois, P., et al. 2004. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. J. Biol. Chem. 279:16154-16160.
50. Froeschl, M., Olsen, S., Ma, X., and O'Brien, E.R. 2004. Current understanding of in-stent restenosis and the potential benefit of drug eluting stents. Curr. Drug Targets Cardiovasc. Haematol. Disord. 4:103-117.
51. Law, R.E., et al. 1996. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J. Clin. Invest. 98:1897-1905.
52. Takagi, T., et al. 2003. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am. Heart J. 146:E5.
53. Choi, D., et al. 2004. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care. 27:2654-2660.
54. Barbier, O., et al. 2003. FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology. 124:1926-1940.
55. Charrier, C., et al. 1996. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichiacoli. J. Virol. 70:4805-4810.
56. Sardet, C., et al. 1995. E2F-4 and E2F-5, two members of the E2F family, are expressed in the early phases of the cell cycle. Proc. Natl. Acad. Sci. U. S. A. 92:2403-2407.
57. Corsini, A., et al. 1996. Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes. J. Cardiovasc. Pharmacol. 28:687-694.
58. Fiszer-Szafarz, B., Szafarz, D., and Guevara de Murillo, A. 1981. A general, fast, and sensitive micromethod for DNA determination application to rat and mouse liver, rat hepatoma, human leukocytes, chicken fibroblasts, and yeast cells. Anal. Biochem. 110:165-170.
59. Kherrouche, Z., De Launoit, Y., and Monte, D. 2004. Human E2F6 is alternatively spliced to generate multiple protein isoforms. Biochem. Biophys. Res. Commun. 317:749-760.
60. Draetta, G., Brizuela, L., Potashkin, J., and Beach, D. 1987. Identification of p34 and p13, human homologs of the cell cycle regulators of fission yeast encoded by cdc2+ and suc1+. Cell. 50:319-325.
61. Vu-Dac, N., et al. 1997. Transcriptional regulation of apolipoprotein A-I gene expression by the nuclear receptor RORalpha. J. Biol. Chem. 272:22401-22404.
62. Lee, S.S., et al. 1995. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotcopic effects of peroxisome proliferators. Mol. Cell. Biol. 15:3012-3022.
63. Zarkowska, T., and Mittnacht, S. 1997. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J. Biol. Chem. 272:12738-12746.
64. Gizard, F., et al. 2004. The transcriptional regulating protein of 132 kDa (TReP-132) differentially influences steroidogenic pathways in human adrenal NCI-H295 cells. J. Mol. Endocrinol. 32:557-569.